ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Renal Cell Carcinoma
Colorectal Cancer
Uveal Melanoma

Melanoma trials near Cleveland, OH, USA:

Neoadjuvant Darovasertib in Primary Uveal Melanoma

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma...

Enrolling
Uveal Melanoma
Procedure: Primary Local Therapy
Drug: Darovasertib

Phase 3

Ideaya Biosciences

Cleveland, Ohio, United States and 93 other locations

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...

Active, not recruiting
Mucosal Melanoma
Melanoma
Drug: Phase 1b: APG-115+pembrolizumab

Phase 1, Phase 2

Ascentage Pharma Group
Ascentage Pharma Group

Cleveland, Ohio, United States and 20 other locations

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)...

Enrolling
Uveal Melanoma
Drug: Crizotinib (Xalkori)
Drug: Darovasertib

Phase 3

Ideaya Biosciences

Cleveland, Ohio, United States and 12 other locations

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...

Active, not recruiting
Advanced or Metastatic NRAS-mutant Melanoma
Drug: Trametinib
Drug: Naporafenib

Phase 3

Erasca

Cleveland, Ohio, United States and 58 other locations

Locations recently updated

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the com...

Enrolling
Melanoma
Drug: fianlimab
Drug: cemiplimab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Cleveland, Ohio, United States and 111 other locations

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Active, not recruiting
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

Phase 3

Aura Biosciences
Aura Biosciences

Cleveland, Ohio, United States of America and 68 other locations

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Active, not recruiting
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Cleveland, Ohio, United States and 67 other locations

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

use the immune system to recognize and kill cancer cells. The study is focused on participants with a type of skin cancer known as melanoma...

Active, not recruiting
Melanoma
Drug: Placebo
Drug: cemiplimab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Cleveland, Ohio, United States and 103 other locations

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127)

not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...

Active, not recruiting
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Cleveland, Ohio, United States and 152 other locations

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Cleveland, Ohio, United States and 130 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems